Infliximab Induction Regimens in Steroid-Refractory Acute Severe Colitis

A Multicentre Retrospective Cohort Study With Propensity Score Analysis

Shaji Sebastian; Sally Myers; Konstantinos Argyriou; Gayle Martin; Louis Los; Joseph Fiske; Ravi Ranjan; Benjamin Cooper; Vivek Goodoory; Hey-Long Ching; NishaniLalanthika Jayasooriya; Johanne Brooks; Anjan Dhar; Achut H. Shenoy; Jimmy K. Limdi; Jeffrey Butterworth; Patrick B. Allen; Sunil Samuel; Gordon W. Moran; Richard Shenderey; Gareth Parkes; Alan Lobo; Nicholas A. Kennedy; Sreedar Subramanian; Tim Raine


Aliment Pharmacol Ther. 2019;50(6):330-335. 

In This Article


In conclusion, we found that in the overall cohort of ASUC patients in real-world setting receiving rescue therapy infliximab, the initial induction dosing strategy did not change the short-term or long-term colectomy rates. In a subgroup of patients with matched covariates of severity, accelerated induction regimes appear to reduce in-hospital and short-term colectomy rates without any increase in complications. The optimal dosing regimens and risk stratification of patients needing accelerated dosing regimens need to be evaluated in a prospective study.